Infectious Diseases (except HIV/AIDS)

Long COVID in cancer patients: preponderance of symptoms in majority of patients over long time period

1. Hiba Dagher
2. Anne-Marie Chaftari
3. Ishwaria M Subbiah
4. Alexandre E Malek
5. Ying Jiang
6. Peter Lamie
7. Bruno Granwehr
8. Teny John
9. Eduardo Yepez
10. Jovan Borjan
11. Cielito Reyes-Gibby
12. Mary Flores
13. Fareed Khawaja
14. Mala Pande
15. Noman Ali
16. Raniv Rojo
17. Daniel D Karp
18. Patrick Chaftari
19. Ray Hachem
20. Issam I Raad

• Curated by eLife

  eLife assessment

  This manuscript reports the results of an observational study in 312 cancer patients to assess post-acute sequelae of SARS-CoV-2 infection (PASC). Their descriptive results provide details on the type of persistent symptoms as well as their frequency among cancer patients. This is valuable information to inform clinical policies regarding disease management in cancer patients.

Reviewed by eLife

Differences in the immune response elicited by two immunization schedules with an inactivated SARS-CoV-2 vaccine in a randomized phase 3 clinical trial

1. Nicolás MS Gálvez
2. Gaspar A Pacheco
3. Bárbara M Schultz
4. Felipe Melo-González
5. Jorge A Soto
6. Luisa F Duarte
7. Liliana A González
8. Daniela Rivera-Pérez
9. Mariana Ríos
10. Roslye V Berrios
11. Yaneisi Vázquez
12. Daniela Moreno-Tapia
13. Omar P Vallejos
14. Catalina A Andrade
15. Guillermo Hoppe-Elsholz
16. Carolina Iturriaga
17. Marcela Urzua
18. María S Navarrete
19. Álvaro Rojas
20. Rodrigo Fasce
21. Jorge Fernández
22. Judith Mora
23. Eugenio Ramírez
24. Aracelly Gaete-Argel
25. Mónica L Acevedo
26. Fernando Valiente-Echeverría
27. Ricardo Soto-Rifo
28. Daniela Weiskopf
29. Alba Grifoni
30. Alessandro Sette
31. Gang Zeng
32. Weining Meng
33. CoronaVacCL03 Study Group
34. José V González-Aramundiz
35. Marina Johnson
36. David Goldblatt
37. Pablo A González
38. Katia Abarca
39. Susan M Bueno
40. Alexis M Kalergis

• Curated by eLife

  Evaluation Summary:

  This manuscript described the effects of two different CoronaVac vaccination schedules in a Chilean adult population. They find that a 0 and 28-day two-dose schedule produced superior levels of neutralizing antibodies and antibodies with a great breadth of interaction across variants compared to a 0 and 14-day two-dose schedule. They find no differences in T cell responses or total antibody levels between the two groups. These findings demonstrate that a short two-week two-dose interval should provide sufficient immunity to reduce the likelihood of serious outcomes during a COVID infection.

  (This preprint has been reviewed by eLife. We include the public reviews from the reviewers here; the authors also receive private feedback with suggested changes to the manuscript. The reviewers remained anonymous to the authors.)

Reviewed by eLife

The burden of human coronavirus infection in children hospitalised with lower respiratory tract infection in Cape Town, South Africa

1. Abdulmumuni S. Aliyu
2. Adelaide N. Masu
3. Benjamin M. Kagina
4. Rudzani Muloiwa

Reviewed by PeerRef

Trends in SARS-CoV-2 infection prevalence during England’s roadmap out of lockdown, January to July 2021

1. Oliver Eales
2. Haowei Wang
3. David Haw
4. Kylie E. C. Ainslie
5. Caroline E. Walters
6. Christina Atchison
7. Graham Cooke
8. Wendy Barclay
9. Helen Ward
10. Ara Darzi
11. Deborah Ashby
12. Christl A. Donnelly
13. Paul Elliott
14. Steven Riley

Reviewed by ScreenIT

Longitudinal profiles of plasma gelsolin, cytokines and antibody expression predict COVID-19 severity and hospitalization outcomes

1. Meshach Asare-Werehene
2. Michaeline McGuinty
3. Agatha Vranjkovic
4. Yannick Galipeau
5. Juthaporn Cowan
6. Bill Cameron
7. Curtis L. Cooper
8. Marc-André Langlois
9. Angela M. Crawley
10. Benjamin K. Tsang

Reviewed by ScreenIT

Investigating the optimum sample type and target genes for SARS-CoV-2 detection

1. Junjie Zhan
2. Ying xie
3. Junxue Wang
4. Xiaofeng Hang

Reviewed by ScreenIT

Homologous and Heterologous Boosting of the Chadox1-S1-S COVID-19 Vaccine With the SCB-2019 Vaccine Candidate: A Randomized, Controlled, Phase 2 Study

1. Sue Ann Costa Clemens
2. Eveline Pipolo Milan
3. Eduardo Sprinz
4. José Cerbino Neto
5. Filippo Pacciarini
6. Ping Li
7. Hui Ling Chen
8. Igor Smolenov
9. Andrew Pollard
10. Ralf Clemens

Reviewed by ScreenIT

Iron status and the risk of sepsis and severe COVID-19: a two-sample Mendelian randomization study

1. Randi Marie Mohus
2. Helene Flatby
3. Kristin V. Liyanarachi
4. Andrew T. DeWan
5. Erik Solligård
6. Jan Kristian Damås
7. Bjørn Olav Åsvold
8. Lise T. Gustad
9. Tormod Rogne

Reviewed by ScreenIT

Severe acute respiratory syndrome coronavirus 2 breakthrough infections in healthcare workers vaccinees with BNT162b2 (Pfizer-BioNtech) in Bogotá, Colombia

1. Pilar Tavera-Rodríguez
2. Juliana Barbosa-Ramírez
3. Andrea Bermúdez-Forero
4. Diego Prada-Cardozo
5. Jhonnatan Reales-González
6. Dioselina Peláez-Carvajal
7. Diana Malo-Sanchez
8. Maria-Ximena Meneses-Gil
9. Marcela Mercado-Reyes

Reviewed by ScreenIT

Symptom variation, correlations, and relationship to physical activity in Long Covid: intensive longitudinal study

1. Christopher Burton
2. Helen Dawes
3. Simon Goodwill
4. Michael Thelwell
5. Caroline Dalton

Reviewed by ScreenIT